openPR Logo
Press release

The Dyslipidemia Therapeutics Market To Lay Greater Emphasis On Clinicians' Satisfaction

08-12-2022 02:38 PM CET | Health & Medicine

Press release from: Persistence Market Research

The Dyslipidemia Therapeutics Market To Lay Greater Emphasis

Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration.

These condition are mainly associated with cardiovascular or coronary heart disease. The other cause of this disease includes hypothyroidism and genetic predisposition. Rise in triglyceride concentration might also lead to the diabetes mellitus, obesity and hypothyroidism. The treatment of dyslipidemia includes lifestyle modification, exercise & weight reduction, nutrition supplement and drug therapy.

Get Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/14401

The global market for dyslipidemia therapeutics is expected to be driven by the increasing incidence of dyslipidemia and cardiovascular disease, growing obese population prone to cardiovascular disease due to sedentary lifestyle. Few of the drivers of the market are the growing R&D activities by leading players for the development of novel drugs, increasing diagnosis rate among patient population and increasing awareness in developing economies.

Moreover, the increasing research activities on stain and non-stain based therapeutics for cardiovascular and associated disease, preclinical research activities and growing collaboration between research institutes, biotechnology and biopharmaceuticals companies are expected to drive the market during the forecast period. However, the high cost of drug development and pre-clinical activities, high cost of therapeutics to the end users, stringent regulation and lengthy approval process might hamper the market growth to some extent.

Dyslipidemia therapeutics market has been segmented on the basis of product type, distribution channel and region.

For entire list of market players, request for Table of content here @ https://www.persistencemarketresearch.com/toc/14401

Based on the product type, the dyslipidemia therapeutics market is segmented into the following:

Statin Drugs
High-intensity
Moderate-intensity
Low-intensity
Non-Statin Lipid-Lowering Drugs
Bile Acid Sequestrants
Cholesterol Absorption Inhibitor
Fibrates
Nicotinic Acid
PCSK9 Monoclonal Antibodies
omega-3 Fatty Acids
Combination Products

Based on the distribution channel, the dyslipidemia therapeutics market is segmented into the following:

Hospitals Pharmacies
Drug Store
Online Pharmacies
Retail Pharmacies

Global dyslipidemia therapeutics market is experiencing significant growth owing to increased need for high cholesterol management, prevention of cardiovascular disease (CVD), and sedentary lifestyle leading to growing obese population across the globe. Based on product type, the market is segmented into stain and non-stain drugs. Stain drugs are majorly used as primary treatment option for dyslipidemia. Stain drugs are classified as high-intensity, moderate-intensity and low-intensity.

Based on distribution channel, the global dyslipidemia therapeutics market has been segmented into hospital pharmacies, drug stores, retail pharmacies, and online pharmacies. Hospital pharmacies distribution channel segment is expected to grow at the higher rate over the forecast period due to increasing purchase of prescription drugs and growing diagnosis rate of dyslipidemia across the globe.

Moreover recent development of for the development of cholesterol lowering drugs, ongoing R&D activities in this therapeutics area and presence of research driven players in the market may help grow this market significantly.

Geographically dyslipidemia therapeutics market is classified into regions viz. North America, Latin America, Europe, Asia-Pacific, Middle East and Africa. North America and Europe will remain key markets for dyslipidemia therapeutics market due to high diagnosis and incidence rate of dyslipidemia due to sedentary lifestyle and obese population prone to cardio vascular disease.

Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/14401

Moreover, presence of sophisticated healthcare infrastructure, awareness about the disease among population and high purchasing power are few of the factors responsible for the market growth. Asia Pacific is anticipated to register positive growth owing to rising government's initiatives in healthcare sector, improved healthcare infrastructure and increased population in the region.

Some of the key players in the dyslipidemia therapeutics market are Novartis AG, Merck & Co., Inc, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Eli Lilly, AstraZeneca plc, Amgen Inc., to name a few. Companies are now focusing on the development of novel therapeutics.

For example, PCSK9 Inhibitors is new therapy used for cholesterol management. In July 2015, FDA approved Alirocumab (Praluent®), a PCSK9 Inhibitor, manufactured by Sanofi and evolocumab (Repatha™), manufactured by Amgen Inc. in August 2015.

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com
Website - https://www.persistencemarketresearch.com

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers' experience by acting as the "missing" link between "customer relationships" and "business outcomes'. The best possible returns are assured therein.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Dyslipidemia Therapeutics Market To Lay Greater Emphasis On Clinicians' Satisfaction here

News-ID: 2704500 • Views: 167

More Releases from Persistence Market Research

Electronic Board Level Underfill And Encapsulation Material Market Sale to Reach …
Electronic Board Level Underfill And Encapsulation Material Market 2022 Electronic Board Level Underfill and Encapsulation Material Market to Reach US$ 483 Mn by 2030-end, Market Gradually Recovering After Initial Setback Due to COVID-19 Outbreak. As such, the global electronic board level underfill and encapsulation material market is estimated to expand at a CAGR of 5.5% by during the forecast period of 2020-2030. To remain 'ahead' of your competitors, request for free samples copy@ https://www.persistencemarketresearch.com/samples/19783 Rapidly growing demand
Aluminum Die Casting Mold Release Agents Market SWOT Analysis of Top Key Player …
Aluminum Die Casting Mold Release Agents Market 2022 Aluminum Die Casting Mold Release Agents Market to Reach US$ 417.0 Mn by 2030-end; Decreased Demand Witnessed from End-use Industries Due to COVID-19 Outbreak. As per PMR analysis, the global aluminum die casting mold release agents market is estimated to expand at a CAGR of around 5% by value during the forecast period of 2020-2030. Request for Free Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/26110 In the
Digitized validation of machine functionality to drive the Conveyor Systems Mark …
Conveyors are mechanical equipment which find application in several industries including automotive, manufacturing, retail, food and beverage, and transportation. Conveyors are used in order to reduce errors that occur while manually handling materials and to save time. Owing to constant changes in industrial demands in terms of expected efficiency and product characteristics multiple conveyor systems have been developed. Major conveyor types include belt, roller, overhead conveyors, tri-planar, crescent conveyor, pallet and
The Vacuum Pumps Market to witness digital representations of production machine …
Vacuum pump is a mechanical device which is used to create vacuum by removing gas molecules from a sealed volume. Growing adoption of vacuum pumps in power, oil & gas, chemical processing, and semiconductor industries is driving the demand for vacuum pumps. Moreover, rising investment in these industries is also expected to benefit the market of vacuum pumps globally. On the basis of types, vacuum pumps market is segmented into five

All 5 Releases


More Releases for Dyslipidemia

Dyslipidemia drugs Market - Growth Dynamics 2025
Global Dyslipidemia Drugs Market: Snapshot Dyslipidemia is a cardiovascular condition comprising of changes in the amount of lipids in the blood. Dyslipidemia can show as either absence of or abundance of lipids in blood; hyperlipidemia, the state of having overabundance lipids in the blood, is probably going to hold the major share in the global dyslipidemia drugs market in the within the forecast period. Various issues related with dietary habits and
Dyslipidemia drugs Market Electrification Rate of 2025
Global Dyslipidemia Drugs Market: Snapshot Dyslipidemia is a cardiovascular condition comprising of changes in the amount of lipids in the blood. Dyslipidemia can show as either absence of or abundance of lipids in blood; hyperlipidemia, the state of having overabundance lipids in the blood, is probably going to hold the major share in the global dyslipidemia drugs market in the within the forecast period. Various issues related with dietary habits and
Global Dyslipidemia Drugs Market Growth after 2017
Qyresearchreports include new market research report Global Dyslipidemia Drugs Sales Market Report 2017 to its huge collection of research reports. This business and commerce study on the global Dyslipidemia Drugs market has been freshly compiled by a group of professional market research analysts and aspires to serve a reliable business tool for the stockholders of this market. The report begins with an overview of the global Dyslipidemia Drugs market, evaluating market
Dyslipidemia - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Dyslipidemia - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H2 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol, the ""bad"" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a
Dyslipidemia - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Dyslipidemia - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2017, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol, the ""bad"" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a
Emerging Opportunities in Dyslipidemia Drugs Market
The top five players in the global dyslipidemia drugs market are AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited, and Abbott Laboratories. The cumulative share of these players in the global market was valued at 74.4% in 2014. The exclusivity in the rights of blockbuster drugs has been the primary growth driver for these companies. Analysts predict that intensive research and development activities by these players